CPSI’s Pilobuc insert is based on a hydrogel polymer technology that delivers drugs to the buccal mucosa. Pilobuc allows for the sustained buccal delivery of pilocarpine while reducing the side effects associated with oral systemic treatments.
Zahed Subhan, CEO of Marillion Pharmaceuticals, said: “Pilobuc is a novel, proprietary, buccal formulation of pilocarpine shown in clinical trials to effectively and conveniently deliver the drug with reduced side effects compared to other routes of administration.”